Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).
Richard M. Stone, MD
Advertisement
Articles by Richard M. Stone, MD
Richard M. Stone, MD, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).
Advertisement
Latest Updated Articles
The Genetic Landscape of AMLPublished: April 12th 2017 | Updated:
Monitoring MRD in Patients with AMLPublished: October 30th 2017 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
